-
Cephalon Inc. v. Dr Reddy's Laboratories Ltd et al DC CAFC
- 1:15-cv-00179
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 02/23/2015
- Closed: 06/29/2017
- Latest Docket Entry: 06/30/2017
- PACER
1
Plaintiff
17
Defendants
8
Accused
Products
3
Patents-in-Suit
858
Days in
Litigation
-
Cephalon Inc. v. Dr Reddy's Laboratories Ltd et al DC CAFC
- 1:15-cv-00179
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 02/23/2015
- Closed: 06/29/2017
- Latest Docket Entry: 06/30/2017
- PACER
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Infringement
Actavis LLC
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,895,756 B2 | All Asserted Claims |
Infringement
Entry 27
|
Breckenridge Pharmaceutical, Inc.
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,895,756 B2 | All Asserted Claims |
Infringement
Entry 27
|
Dr. Reddy's Lab., Inc.
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,895,756 B2 | All Asserted Claims |
Infringement
Entry 27
|
Dr. Reddy's Laboratories Ltd.
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,895,756 B2 | All Asserted Claims |
Infringement
Entry 27
|
Emcure Pharmaceuticals Limited
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,895,756 B2 | All Asserted Claims |
Infringement
Entry 27
|
Hetero Labs Limited
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,895,756 B2 | All Asserted Claims |
Infringement
Entry 27
|
Hetero USA Incorporated
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,895,756 B2 | All Asserted Claims |
Infringement
Entry 27
|
Hospira Incorporated
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,895,756 B2 | All Asserted Claims |
Infringement
Entry 27
|
Natco Pharma Limited
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,895,756 B2 | All Asserted Claims |
Infringement
Entry 27
|
Pharmascience Incorporated
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,895,756 B2 | All Asserted Claims |
Infringement
Entry 27
|
Sagent Pharmaceuticals Incorporated
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,895,756 B2 | All Asserted Claims |
Infringement
Entry 27
|
Sun Pharmaceutical Industries Limited
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,895,756 B2 | All Asserted Claims |
Infringement
Entry 27
|
Sun Pharma Global Fze
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,895,756 B2 | All Asserted Claims |
Infringement
Entry 27
|
Wockhardt Limited
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,895,756 B2 | All Asserted Claims |
Infringement
Entry 27
|
Wockhardt USA LLC
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,669,279 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,883,836 B2 | All Asserted Claims |
Infringement
Entry 27
|
| 25 mg/vial, 100 mg/vial bendamustine hydrochloride powder for infusion | US 8,895,756 B2 | All Asserted Claims |
Infringement
Entry 27
|
